Please join us for an informative seminar presented by

The Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, Massachusetts 02115

October 7, 2005
7:30 am Registration and continental breakfast
8:00 am Conference

The emergent understanding of the molecular basis of disease is transforming the practice of medicine. And with this understanding medicine is moving from its conventional course of symptomatic disease management to a new era of individualized medicine and pre-symptomatic disease management.

Personalized medicine will redefine all aspects of health care delivery: for the companies that provide the innovations; for the way patients view their health, their disease, and the quality of the care they receive; and for the traditional systems that govern and pay for life sciences and health care. Many of the traditional relationships among health care innovators, providers, and consumers are about to change dramatically. Biotech, pharma, and equity investors will face new models of practice and payments in this changed landscape. Patients, physicians, and payors will have rapidly evolving, competing ideas of what constitutes good health care.

Boston’s thought leaders in personalized medicine will gather at the Harvard Medical School New Research Building to discuss and debate the issues that are related to this oncoming shift in health care delivery: How are their institutions coping, where are they seeing immediate benefits in health care delivery, what are the current issues, where are the roadblocks, and what will the deal breakers be in the future?
Renowned cancer researcher Judah Folkman has spent his life thinking outside the box and will speak on ushering in the age of biomarkers and pre-symptomatic therapy. Then a distinguished panel representing all aspects of health care delivery, from discovery through patient care, will discuss how their organizations are evolving in this area and what changes stakeholders need to effect in order to optimize personalized medicine health care delivery.

Bringing personalized medicine products to market in this evolving landscape presents a unique set of challenges. The leaders in molecular medicine will be those who have prepared strategies that enable them to anticipate, incorporate, and take advantage of the changes that grow out of this revolution in health care. During the second half of the morning, thought leaders will address these new challenges and will share their views on the critical path to successful business models.

We look forward to your participation in this exciting program.